Skyrizi, generically known as risankizumab, is a prescription medication used in the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is also indicated for the treatment of active psoriatic arthritis in adults. Skyrizi is a biologic medication that works by targeting a specific protein in the body, interleukin-23 (IL-23), which plays a key role in the inflammation and development of psoriasis and psoriatic arthritis. By inhibiting the action of IL-23, Skyrizi helps to reduce the symptoms of these conditions, including reducing skin plaques and joint pain, thereby improving the quality of life for patients. It is administered through subcutaneous injection and is typically prescribed by a healthcare professional experienced in the diagnosis and treatment of psoriasis or psoriatic arthritis.